Resumen
Prostate cancer (PCa) is the second most diagnosed malignancy in men. PCa is a heterogeneous disease, with the clinical presentation ranging from localized and indolent to a rapidly progressing lethal metastatic disease, therefore, we needed the predictor to diagnosis of aggressive PCa. The most important predictor of PCa outcomes has been demonstrated to be the histological Gleason score which was confirmed after prostate biopsy. In this study, we found that germline variants of ARRDC4 and UBXN1 could affect the prostate cancer Gleason score, which could be a potential marker to select aggressive PCa.